The new bariatric surgery guidelines
cite effectiveness, cost efficiency, and safety as reasons to
consider the procedure. With all the problems I am finding, I have
serious doubts about the long-term safety.
The International Diabetes Federation
Taskforce on Epidemiology and Prevention of Diabetes convened a
consensus working group of diabetologists, endocrinologists, surgeons
and public health experts to review the appropriate role of surgery
and other gastrointestinal interventions in the treatment and
prevention of type 2 diabetes. The specific goals were: to develop
practical recommendations for clinicians on patient selection; to
identify barriers to surgical access and suggest interventions for
health policy changes that ensure equitable access to surgery when
indicated; and to identify priorities for research.
Bariatric surgery can significantly
improve glycemic control in severely obese patients with type 2
diabetes. It is an effective, safe (questionable) and cost-effective
therapy for these patients. Surgery can be considered an appropriate
treatment for people with type 2 diabetes and obesity that have not
achieved the recommended treatment targets with medical therapies,
especially in the presence of other major comorbidities. The
procedures must be performed within accepted guidelines and require
appropriate multidisciplinary assessment, comprehensive patient
education and ongoing care, as well as safe and standardized surgical
procedures.
The last sentence above does describe
what must be done and has not been done in the past by a lot of
surgeons and primary care physicians or other doctors.
Metabolic, or weight-loss, surgery
quickly and dramatically improves blood glucose control. Until now,
however, it has not been included in clinical practice guidelines as
a treatment option for people with diabetes. The Statement and
Clinical Guidelines were published in the June 2016 issue of Diabetes
Care, available in print and online on May 24, 2016.
Despite continuing advances in diabetes
pharmacotherapy, fewer than half of adults with type 2 diabetes
attain therapeutic goals designed to reduce long-term risks of
complications, especially for glycemic control, and lifestyle
interventions are disappointing in the long term. Metabolic surgery,
on the other hand, has been shown to improve glucose homeostasis more
effectively than any known pharmaceutical or behavioral approach.
Despite such evidence, to date, metabolic surgery had not been
included in clinical guidelines for diabetes care as a recommended
intervention.
According to the new guidelines,
metabolic surgery should be recommended to treat type 2 diabetes in
patients with Class III obesity (BMI greater than or equal to 40
kg/m2), as well as in those with Class II obesity (BMI between 35 and
39.9 kg/m2) when hyperglycemia is inadequately controlled by
lifestyle and medical therapy. It should also be considered for
patients with type 2 diabetes who have a BMI between 30 and 34.9
kg/m2 if hyperglycemia is inadequately controlled. The Consensus
Statement also recognizes that BMI thresholds in Asian patients, who
develop type 2 at lower BMI than other populations, should be lowered
2.5 kg/m2 for each of these categories.
These conclusions are based on a large
body of evidence, including 11 randomized clinical trials showing
that in most cases surgery can either reduce blood glucose levels
below diabetic thresholds (“diabetes remission”) or maintain
adequate glycemic control despite major reduction in medication
usage. While relapse of hyperglycemia may occur in up to 50% of
patients with initial remission, most patients maintain substantial
improvement of A1C long term.
Economic studies also show that
metabolic surgery is cost-effective. The authors of the new
guidelines recommend that healthcare regulators introduce appropriate
reimbursement policies for metabolic surgery for people with type 2
diabetes.